GTXI - GTx, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

GTx, Inc.

175 Toyota Plaza
7th Floor
Memphis, TN 38103
United States
901-523-9700
http://www.gtxinc.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees26

Key Executives

NameTitlePayExercisedAge
Dr. Robert James Wills Ph.D.335.26kN/A63
Mr. Marc S. Hanover MBA620.77kN/A54
Mr. Henry P. Doggrell479.32kN/A68
Mr. Jason T. ShackelfordN/AN/A42
Dr. Diane C. Young M.D.N/AN/A60
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). The company’s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Corporate Governance

GTx, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.